Methods Of Treating Fabry Patients Having Renal Impairment

A method of stabilizing renal function in a patient diagnosed with Fabry disease and having renal impairment, the method comprising:

• administering to a Fabry disease patient about 100 mg to about 150 mg free base equivalent (FBE) of migalastat at a frequency of once every other day, wherein the Fabry disease patient has moderate or severe renal impairment with an eGFR less than 60 mL/min/1.73 m2 and a HEK assay amenable α-galactosidase A mutation,
• wherein the administration is effective to (i) reduce left ventricular mass index (LVMi) in the patient, and (ii) provide a mean annualized rate of change in eGFRCKD-EPI of greater than −1.0 mL/min/1.73 m2.